Dose-ranging Study to Evaluate Antibody Response to G17DT in Patients With Gastric Cancer

Inclusion Criteria

Stage I-III Criteria- - Patients aged 18 years or over who had had a macroscopically curative resection for gastric adenocarcinoma. - Absence of metastatic disease evident from: - physical examination - the most recent chest X-ray - abdominal CT or ultrasound scan - Life expectancy of at least 3 months - WHO performance status of 0 to 1 - Written informed consent given Stage IV Criteria- - Patients aged 18 years or over with Stage IV gastric cancer: carcinoma with the primary tumour invading the adjacent structures and/or involvement of more than 15 regional lymph nodes and/or distant metastases - Life expectancy of at least 3 months - WHO performance status of 0 to 2 - Written informed consent given

Exclusion Criteria

- History of other malignant disease except non-melanomatous skin cancer or in situ carcinoma of the uterine cervix Recurrent gastric cancer following previous surgery Presence of metastatic disease: peritoneal deposits or involved lymph nodes outside the limit of resection - Previous use, concomitant use or anticipated use in the period of the study, of any anti-cancer therapies - Concomitant use of immunosuppressants, including systemic (ie oral or injected) corticosteroids - Females who were pregnant, planning to become pregnant or lactating - Patients who were taking part in another study involving an investigational or licensed drug or device in the three months preceding enrolment or during this study - Previous G17DT treatment - Haematological indicators: - Haemoglobin <10.0g/dl - White blood cell count <4.0 x 109/l - Platelets <100 x 109/l